Biopharma Leader Joseph Mulvey Joins CMT Research Foundation Board of Directors to Help Deliver Treatments & Cures
The CMT Research Foundation, a nonprofit solely focused on delivering treatments and cures for Charcot-Marie-Tooth disease, is pleased to announce that Joseph Mulvey, MBA, PMP, has joined its board of directors. Mr. Mulvey is the founder and president of...
Turning $128,000 into Millions to Deliver a Treatment for CMT
If you’ve ever been frustrated by the slow pace of research progress or questioned how a single donation makes a difference, the collaboration between the CMT Research Foundation and DTx Pharma proves that one simple action, one bold move and one donation is all...
What to Expect in CMT Research During 2021: 5 Questions with Chief Scientific Officer Keith Fargo
What progress can patients and families expect to see in CMT research during 2021? What is the most promising research on the horizon? The CMT Research Foundation’s Chief Scientific Officer Keith Fargo, Ph.D., sat down with us to answer your most pressing questions...
Dr. Bruce D. Carter Joins Scientific Advisory Board to Help CMT Research Foundation Deliver Treatments and Cures
The CMT Research Foundation is pleased to announce that Bruce D. Carter, Ph.D., has joined the organization’s Scientific Advisory Board to help guide research strategy and funding to deliver treatments and cures for Charcot-Marie-Tooth (CMT) disease. Dr. Carter is a...
Peter J. deSilva Joins CMT Research Foundation Board of Directors to Help Speed Treatments & Cures
The CMT Research Foundation is pleased to welcome Peter J. deSilva as the newest member of its board of directors. With more than 30 years of experience as a results-oriented leader in the financial sector, Mr. deSilva will bring his world-class expertise in strategic...
Important Research News Announcements
- Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study January 9, 2021
- Epigenetic Regulation of CMT: A Lesson from Drosophila Models January 7, 2021
- Clinical features of homozygous FIG4-p.Ile41Thr Charcot-Marie-Tooth 4J patients January 6, 2021
- Aberrant Splicing in GJB1 and the Relevance of 5′ UTR in CMTX1 Pathogenesis December 28, 2020
- Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease December 20, 2020
- Neurogene adds another $115M to the pot for trials for its gene therapies, including its CMT4J program December 18, 2020
- More Than Hope: An Action Plan to End CMT December 18, 2020
- Aminoacyl-tRNA synthetases in Charcot-Marie-Tooth disease: a gain or a loss? November 26, 2020
- The expanding genetic landscape of hereditary motor neuropathies November 19, 2020
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Type 1A (CMT1A) November 19, 2020